Key Highlights
- AbbVie approaches final stages of a $10.9 billion cash acquisition of Apogee Therapeutics (APGE)
- The proposed purchase price represents approximately 60% above Apogee’s $90.38 share price from June 18
- JPMorgan maintains Buy rating on ABBV, highlighting strong strategic alignment
- Apogee’s primary candidate, zumilokibart, shows promise as a potential Dupixent competitor for atopic dermatitis
- ABBV shares declined more than 2% Friday; APGE shares climbed approximately 2%
AbbVie has entered final-stage negotiations to purchase clinical-stage biotechnology firm Apogee Therapeutics through an all-cash transaction valued at around $10.9 billion. The bid represents approximately a 60% markup over Apogee’s $90.38 share price from June 18. Shares of ABBV fell more than 2% Friday, whereas APGE climbed roughly 2% following the disclosure.
According to Reuters, a formal announcement could arrive as soon as Monday, June 22, though both companies have yet to issue public statements regarding the discussions.
This transaction would represent AbbVie’s most significant acquisition since completing its $63 billion Allergan purchase in 2019. However, unlike Allergan, which brought established products and revenue streams, Apogee currently has no marketed therapies generating sales.
Apogee operates as a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease. The company’s entire development portfolio centers on a single primary asset: zumilokibart.
Zumilokibart works by targeting IL-13, a cytokine responsible for driving inflammatory responses in atopic dermatitis. Clinical trial results suggest the therapy may need administration only twice annually, a significant improvement over certain existing treatments requiring up to 26 injections yearly.
JPMorgan Highlights Strategic Value
JPMorgan analyst Chris Schott maintained his Buy recommendation on ABBV following the acquisition reports. He described the transaction as strategically advantageous, emphasizing AbbVie’s extensive immunology expertise as crucial for successfully commercializing zumilokibart upon potential approval.
Schott further observed that zumilokibart could emerge as a direct competitor to Dupixent, the highly successful therapy jointly marketed by Sanofi and Regeneron that currently leads the atopic dermatitis treatment landscape.
He anticipates AbbVie would implement an extensive development strategy for the compound, and that this acquisition bolsters the company’s late-stage development portfolio — an area under close investor scrutiny.
ABBV holds a Strong Buy consensus rating on TipRanks, supported by 16 Buy recommendations and 5 Hold ratings across the last three months. The average price target stands at $254.71, suggesting potential upside of approximately 17.65%.
Pipeline Sustainability Concerns
AbbVie’s three leading immunology products — Skyrizi, Rinvoq, and Humira — produced combined revenues of $30.4 billion in 2025, representing 14% growth year over year. However, Humira faces ongoing erosion from biosimilar competition.
While Skyrizi and Rinvoq are currently offsetting Humira’s decline, this compensatory growth has finite duration. AbbVie has pursued a strategy of acquiring early-stage assets instead of waiting for their maturation.
In the previous year, the company committed up to $2.1 billion for Capstan Therapeutics, a developer of Phase 1 autoimmune cell therapies. The Apogee acquisition represents a substantially larger and earlier-stage investment than previous deals.
Apogee had previously arranged up to $1.3 billion in financing from Blackstone Life Sciences this past May to support Phase 3 trials for zumilokibart. AbbVie would essentially purchase access to that trial program before any regulatory decisions are finalized.
Apogee’s valuation reached approximately $6.8 billion before acquisition reports emerged, having risen nearly 20% year to date. AbbVie’s proposed $11 billion purchase price values future possibilities rather than existing commercial products.
